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ABSTRACT
The chromatin remodeling complexes alter chromatin structures. They 
remodel nucleosomes in ATP-dependent manner and have essential roles in 
DNA damage repair, recombination, replication and transcriptional control. 
Increasing evidences indicate that subunits of chromatin remodelers are 
mutated and/or deregulated in a number of human cancers, and how they 
influence the cancer gene expression program during cancer initiation and 
progression is becomming clearer. Therefore, chromatin remodeling complexes 
arose as promising new targets for the treatment of human cancers. In this 
review, chromatin remodeling complexes, their epigenetic reader domains and 
available inhibitors are described. The insights into the misregulated chromatin 
remodelers pathways in human malignancies and the novel approach targeting 
deregulated chromatin remodelers to improve chemotherapy efficiency are 
discussed. 
Chromatin remodelers, epigenetic reader domains and 
their therapeutic potentialA nucleosome is a basic unit of DNA packaging in humans, consisting of 146 bp DNA wrapped around a histone octamer. To control the accessibility of nucleosomal DNA target sites cells have evolved molecular machines, chromatin remodelers. Chromatin remodelers use the ATP-hydrolysis energy to alter the interactions between the nucleosomes and DNA: reposition nucleosomes, evict 
or influence their assembly and composition on the DNA strand and thereby regulate the cellular processes such as transcription, replication, recombination and DNA repair. Human cells carry different chromatin remodelers and to ensure the healthy status of the cell, chromatin remodelers must be in the right place, at the right time and with the right activity1.Chromatin remodelers are composed of the catalytic subunit, which is usually accompanied by one or several accessory subunits. Catalytic subunit contains conserved ATPase domain which belong to Snf2 family of helicase-like proteins and unique protein domains2. Based on unique protein domains, chromatin remodelers fall into 4 families: SWI/SNF, ISWI, CHD and INO80 (Figure. 1)3. These families differ in their epigenetic reader domains, which recognize 
and bind to specifically modified histone tails. For example, SWI/SNF family remodelers contain bromodomain at their C-terminus, which binds acetylated histone tails. CHD family remodelers at their N-terminus harbor chromodomains that bind methylated 
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histone tails. Furthermore, the complexity and specificity 
of chromatin remodeling complexes is achieved by their accessory subunits, that contain additional epigenetic reader domains, RNA binding domains or even form 
complexes with histone deacethylases (HDAC) and histone methyltransferases (HMT)2. 
Malignant cell abuses chromatin remodelers in 
different ways To meet the demands of growth, cancer cells reprogram their metabolism. The connection between cancer and chromatin remodelers arose two decades ago, when SNF5 gene, which encodes a member of the chromatin-
remodelling SWI/SNF complex, was found to be mutated 
in malignant rhabdoid tumours4. Since then, evidence has been accumulating how the deregulated chromatin remodelers can support the uncontrolled growth of the cell.
Loss of expression
Absence of functional chromatin remodeling complexes 
seem to fuel tumour progression. For example, up to 90% small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) harbour inactivating mutations in the chromatin remodelling gene brg1 with concomitant loss of its encoded 
protein Brg1, one of two mutually exclusive ATPases of the 
SWI/SNF chromatin remodelling complex5–8. Moreover, recent studies have shown that Brm, the other mutually 
Figure 1: Catalytic subunits of chromatin remodelers fall into four families.  They share conserved ATPase domain and differ in their 
unique protein domains. Catalytic subunit is shown in green, ATPase domain is in yellow, DNA is blue and nucleosomes are depicted 
in grey.
Manelyte L. J Rare Dis Res Treat. (2017) 2(3): 34-40 Journal of Rare Diseases Research & Treatment
Page 36 of 40
exclusive ATPase of the SWI/SNF complex, is lost in SCCOHT as well and that restoration of either SWI/SNF ATPases can inhibit the growth of SCCOHT cell lines9,10. Brg1 was also 
lost or mutated in a significant number of human lung tumor cell lines and primary non-small cell lung carcinoma clinical specimens11,12. Almost one-third of endometrial undifferentiated carcinomas show loss of Brg1 and Brm 
expression. The majority of the Brg1-deficient cases 
show concominant loss of Brm expression13. Frameshift 
mutation and loss of expression of chd genes are common in gastric cancers (GC) and colorectal cancers (CRC) with 
high microsatellite instability. Loss of Chd4 expression was 
observed in 56.4% of the GCs and 55.7% of the CRCs, and 
loss of Chd8 was observed in 35.7% of the GCs and 28.6% of the CRCs14. Finally, high levels of Snf2L expression in 
normal melanocytes contrast with undetectable expression in malignant melanoma. Depletion of Snf2L in HeLa cells led to enhanced proliferation and increased migration. These 
phenomena were explained by transcriptome profiling, 
which identified Snf2L as a modulator of the Wnt signaling 
network15. Thus, examples above show that the complete 
loss of particular chromatin remodeler expression is one of 
the way to support specific cancer cell.
Interaction with long non-coding RNAThere are mounting evidence, that interaction with RNA is another feature and possibility to control chromatin remodeling machines. Therefore it is not surprising that cancer cells use it to support uncotrolled 
cell division. Catalytic subunits of the SWI/SNF complex, Brg1 and Brm have been described to be regulated by 
lncRNA. For example, high expression of UCA1 (long non-coding RNA urothelial carcinoma associated 1) promotes bladder cancer cell proliferation by inhibiting chromatin 
remodeler Brg1. Depletion of UCA1 by RNAi resulted in upregulated p21 levels and inhibition of cell replication, 
while overexpressed UCA1 reduced p21 protein and 
promoted cell growth. UCA1 highly expressed tissue 
samples are often with Brg1 high expression and it was 
found that UCA1 impairs both binding of Brg1 to the p21 
Figure 2: Malignant cells abuses chromatin remodelers in different ways. Some recent examples of deregulated catalytic 
subunits of chromatin remodelers.
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promoter and chromatin remodeling activity of Brg116. Another long noncoding RNA (lncRNA) called lncBRM 
is highly expressed in liver cancer stem cells (CSCs) and hepatocellular carcinoma (HCC) tumours. LncBRM is required for the self-renewal maintenance of liver CSCs and tumour initiation. In liver CSCs, lncBRM associates with Brm to initiate the Brg1/Brm switch and the Brg1-
embedded BAF complex triggers activation of YAP1 (yes-
associated protein 1) signalling. Moreover, expression 
levels of lncBRM together with YAP1 signalling targets are positively correlated with tumour severity of HCC patients17. It has been discussed in the literature, that the 
interaction between lncRNAs and the SWI/SNF complexes can be divided into two models in cancer: the binding model and the recruiting model. The binding model states that lncRNAs can directly bind to the subunit of the SWI/
SNF complexes and serve as a guide to anchor the SWI/
SNF complexes or function as a decoy to keep chromatin 
modifiers away from specific genomic sites. The recruiting 
model involves lncRNAs recruited SWI/SNF complexes or some core subunits to the target gene, thereby affecting the 
gene structure and expression18. 
Overexpression
Overexpression without mutation of chromatin remodeler proteins is another way of how chromatin remodelers contribute to cancer. This group is of particular interest because of its promise for epigenetic 
therapy. For example, overexpression of Brg1 correlates with colon cancer progression through upregulating 
WNT3A expression. Knocking down Brg1 expression 
significantly suppressed the proliferation and invasion in colon cancer cells19. In breast cancer, Brg1 was 
overexpressed and upregulated de novo lipogenesis, which 
is crucial for cancer cell proliferation. Knockdown of Brg1 attenuated lipid synthesis by impairing the transcription of enzymes catalyzing fatty acid and lipid synthesis. 
Remarkably, exogenous addition of palmitate, the key intermediate in fatty acid synthesis, rescued the cancer cell proliferation defect caused by Brg1 knockdown20. Snf2H 
was overexpressed in human gliomas and contributed to glioma proliferation, invasion, and chemoresistance 
through regulation of cyclin E and NF-κB pathway, which is dependent on its interaction with Rsf-121. Snf2H was 
also overexpressed in breast cancers and contributed to cancer cell proliferation, invasion and correlated 
with poor prognosis. Snf2H overexpression correlated 
with Rsf-1 expression levels and downregulated cyclin 
A, MMP2 expression and upregulated p21 expression22. 
The expression of Ino80, the SWI/SNF ATPase of INO80 
complex, was elevated in melanoma cells and patient melanomas. Ino80 silencing selectively inhibited melanoma cell proliferation, anchorage-independent growth, tumorigenesis, and tumor maintenance. 
Mechanistically, Ino80 occupies >90% of superenhancers, and its occupancy is dependent on transcription factors 
such as MITF and Sox9. Ino80 binding reduces nucleosome occupancy and facilitates Mediator recruitment, thereby promoting oncogenic transcription. Consistently, genes co-
occupied by Ino80 and Med1 are selectively expressed in melanomas compared with melanocytes23. Ino80 was highly 
expressed in cervical cancer cell lines and tumor samples and promoted cell proliferation and tumorigenesis24. 
Ino80, is highly expressed in non-small-cell lung cancer (NSCLC) cells compared with normal lung epithelia 
cells. Its expression, as well as that of another subunit Ino80B, negatively correlates with disease prognosis in lung cancer patients. Functionally, Ino80 silencing inhibits NSCLC cell proliferation and anchorage-independent growth and tumor formation. It occupies enhancer regions near lung cancer-associated genes, and its occupancy correlates with increased genome accessibility and 
enhanced expression of downstream genes25. Baz2A, a factor previously implicated in epigenetic rRNA gene 
silencing, is overexpressed in prostate cancer and is involved in maintaining prostate cancer cell growth. Baz2A regulates numerous protein-coding genes and directly interacts with EZH2 to maintain epigenetic silencing at 
genes repressed in metastasis. Baz2A overexpression is tightly associated with a molecular subtype displaying a CpG island methylator phenotype26. Chormatin remodeler Lsh, furthered malignant progression of nasopharyngeal carcinoma (NPC) by modifying cancer cell metabolism to support epithelial-mesenchymal transition (EMT). Lsh 
expression was increased in NPC, where it was controlled by the Epstein-Barr virus-encoded protein LMP1. In NPC cells Lsh promoted cancer progression in part by 
regulating expression of fumarate hydratase (FH), a core 
component of the tricarboxylic acid cycle. Lsh bound to the 
FH promoter, recruiting the epigenetic silencer factor G9a to repress FH transcription. Clinically, it was found that the 
concentration of TCA (tricarboxylic acid) intermediates in NPC patient sera was deregulated in the presence of Lsh27. 
Thus, increased expression of chromatin remodelers in cancer is a wide and diverse group with its clinical potential as biomarker uses as well as therapeutics.
De Novo mutations in chromatin remodelers
 These alterations contribute to cancer pathogenesis 
by deregulating chromatin remodelers. Whole-exome sequencing of Sézary syndrome tumor-normal sample 
pairs and mutation analysis identified somatic mutations in chromatin remodelers Brg1 and Chd328. Chromatin modifying genes including SETD2, Ino80 and ARID1B were commonly mutated in hepatosplenic T cell lymphoma, 
affecting 62% of cases29. Chd4 among other five proteins 
was idenified carrying the most relevant somatic oncogenic mutations in quadruple wild-type gastrointestinal stromal 
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tumors is a genomic subgroup lacking KIT/PDGFRA/RAS pathways mutations, with an intact succinate 
dehydrogenase complex30. De novo mutations in chromatin 
remodeling complexes could possibly lead to structural or even functional changes, i.e. chromatin remodeling 
complexes are not properly formed and not targeted to the right loci (loss-of-function mutation) or targeted to another DNA loci (gain-of-function mutation).
Targeting chromatin remodelers to improve 
treatment efficiency in precision medicineIt is known that epigenetic regulation plays an essential 
role in tumor development and epigenetic modifiers are 
considered potential druggable candidates. For example, Chd4 was described as a potential pharmacological target to inhibit breast cancer growth. Chd4 silencing 
significantly reduced tumor growth and proliferation of MCF10DCIS.com cells (human breast cancer cell line, known for its capability of recapitulating the various stages of the malignancy when transplanted in an immune-compromised host). Chd4 depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated with 
up-regulation of CDKN1A (p21)31. On the other hand, 
exsisting cancer therapies are not that efficient, some 
patients are developing chemoresistance, which is a major 
barrier to efficient chemotherapy. Recent reports show, 
that inhibiting specific chromatin remodelers actually 
improve treatment efficiencies. For example, gemcitabine is a standard chemotherapeutic agent for locally advanced and metastatic pancreatic cancer. However, some cells establish acquired chemoresistance and Brg1 knockdown can effectively reverse the chemoresistance to gemcitabine. Brg1 promotes both intrinsic and acquired chemoresistance of pancreatic cancer cells, and Brg1 crosstalks with Akt signalling to form a positive feedback loop to promote pancreatic cancer development32. Chd4 plays a crucial role in chemoresistance and the maintenance of stemness in liver cancer stem cells (CSCs) and its targeting suppresses the advanced hepatocellular carcinoma growth. Therefore, Chd4 was suggested as a novel therapeutic target in liver CSCs33. Moreover, inhibition of Chd4 has the potential to 
enhance the effectiveness of genotoxic agents used in acute meloid leukemia therapy34. However, loss of Chd4 confers cisplatin resistance and thereby modulates therapeutic response in BRCA2 mutant ovarian cancer cells. BRCA2 
mutant ovarian cancers with reduced Chd4 expression significantly correlate with shorter progression-free survival and shorter overall survival35. Chemotherapies such as the topoisomerase II (TopoII) inhibitor etoposide effectively reduce disease in a minority of patients with non-small-cell lung cancer. A promising potential epigenetic target is the methyltransferase EZH2. EGFR and Brg1 mutations are genetic biomarkers that predict enhanced sensitivity to TopoII inhibitor in response to EZH2 
inhibition. Brg1 loss-of-function mutant tumours respond to EZH2 inhibition with increased S phase, anaphase bridging, apoptosis and TopoII inhibitor sensitivity. Conversely, EGFR and Brg1 wild-type tumours upregulate Brg1 in response to EZH2 inhibition and ultimately become more resistant to TopoII inhibitor. EGFR gain-of-function mutant tumours are also sensitive to dual EZH2 inhibition and TopoII inhibitor, because of genetic antagonism between EGFR and Brg136. Moreover, ectopic expression of the 
Brg1-bromodomain (Brg1-BRD) construct inhibits γ-H2AX and DNA double-strand break repair after irradiation and increases the radiosensitivity in various human cancer cells, 
including HT29 colon cancer. Brg1-BRD radiosensitizes tumour cells by a dominant negative activity against Brg137. Thus, mountig evidence show the opportunity of targeting chromatin remodelers in precision medicine to treat the 
genetically complex diseases such as cancer.Recently, epigenetic reader domains of chromatin remodelers arose as possible future targets in cancer therapy. Structures of bromodomains were solved38,39 
and specific inhibitors Baz2-ICR, GSK2801 and Pfi-3 of bromodomains of Baz2A/Baz2B and Brg1 were created40–42. It was shown that exposure of embryonic stem 
cells to chemical probe Pfi-3 led to deprivation of stemness 
and deregulated lineage specification42. However, several studies reported that inhibition of bromodomain of Brg1 
had no effect on cancer cell viability. Pfi-3 inhibitor was used in triple negative breast cancer cells and other cancer cells 
and did not influence the proliferation rate of the cancer 
cell lines. But then, specifically targeting the ATPase domain of Brg1 with ADAADiN (active DNA-dependent ATPase A 
domain inhibitor) molecule significantly decreased triple negative breast cancer cell proliferation43. GSK2801 seem 
to have excellent selectivity for Baz2A and Baz2B, with only 
low micromolar residual activity at BRD9 (bromodomain 
containing 9) and TAF1L (TATA-box binding protein associated protein like 1)  and was shown to displace GFP-tagged Baz2A bromodomain from chromatin41. However, 
the effect of GSK2801 on various cancer cell proliferation remain unknown.
Conclusion Deregulated chromatin remodelers arose as additional players in the cellular malignancy. There are mounting evidence that variety of cancers employ chromatin remodelers: they can be downregulated/lacking functional 
protein, increased expression, carry somatic mutations or support cancer through the interaction with long noncoding RNA. In parallel, the promise of epigenetic therapies is growing. It seems that targeting deregulated chromatin remodeling machines is additional level of personalizied medicine and has a promise to increase the 
efficiency of cancer treatment. Thus, further understanding the mechanisms how chromatin remodelers act in cancer 
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and exploring their pharmaceutical potential might lead to 
more efficient therapies. 
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